What’s New

ARVO: Preliminary results concerning the safety and tolerability of Isarna's ISTH0036, a potent and selective antisense oligonucleotide targeting TGF-β2, in patients with glaucoma will be presented during the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 1-5 in Seattle, Washington. Meet us at >>